Docoh
Loading...

Tue. 23 Nov 2021, 7:24am ETBenzinga
In: News, Price Target, Initiation, Analyst Ratings
Evercore ISI Group analyst Maneka Mirchandaney initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform rating and announces Price Target of $68.